Crassula Pharmaceuticals

Q-NiFlex™ and Phytosome Quantum Nano Sphere (PQNS™) Technology: A Next-Generation Multi-Target Drug Delivery Strategy for Joint Health and Osteoarthritis Management

Erwin De La Rosa — Thu, 16 Jul 2026 21:58:41 +0000

Q-NiFlex and Phytosome Quantum Nano Sphere (PQNS) Technology: A Next-Generation Multi-Target Drug Delivery Strategy for Joint Health and Osteoarthritis Management

Issue - 07 |
July - 2026 |
PRINT ISSN No. 2277 - 8179

Published review outlines the multi-target formulation and nano-delivery mechanism; a 500-patient randomized controlled trial is underway to evaluate clinical outcomes

A peer-reviewed paper published in the International Journal of Scientific Research (Vol. 15, Issue 7, July 2026; DOI: 10.36106/ijsr) outlines the scientific rationale behind Q-NiFlex^TM, a multi-component nutraceutical for joint health, and its proprietary Phytosome Quantum Nano Sphere (PQNS) delivery technology.

The paper, authored by Dr. Pallavi Singh (BDS, MDS, Government Hospital, Indore, M.P.) and Dr. Raj Bhan Singh (MD Anesthesiology, Assistant Professor, ESIC Medical College & Hospital, Indore, M.P.), reviews how PQNS combines phytosome complexation with nano-sized vesicular delivery — an approach intended to improve the stability, gastrointestinal protection, and systemic bioavailability of phytoconstituents that are otherwise poorly absorbed, such as curcumin and other botanical extracts.

Q-NiFlex^TM combines glucosamine sulphate, chondroitin sulphate, hyaluronic acid, Boswellia serrata, Curcuma longa, Cissus quadrangularis, and a range of complementary botanicals, amino acids, vitamins, and minerals in a once-daily tablet, formulated to address five functional domains relevant to osteoarthritis: structural cartilage support, inflammation modulation, oxidative stress reduction, connective tissue regeneration, and delivery optimization.

“Osteoarthritis is a multifactorial condition, and single-ingredient supplements have struggled to address that complexity,” the authors note in the paper. “Q-NiFlex^TM was developed on a multi-target philosophy, and PQNS is the delivery system intended to make that formulation more bioavailable.”

Clinical study underway

The paper is explicit that mechanistic rationale is not the same as clinical proof. A prospective, randomized, placebo-controlled study is currently underway to evaluate the efficacy and safety of Q-NiFlex^TM in approximately 500 osteoarthritis patients, with a 12-week treatment period and follow-up to 16 weeks. Primary endpoints include change in WOMAC score from baseline; secondary endpoints include VAS pain scores, physician global assessment, and safety labs.

“Independent, peer-reviewed clinical trial results will be essential to validate the proposed advantages of PQNS technology,” the authors write. No efficacy claims are made pending that trial’s results.

About the PQNS platform

PQNS is a phytosome- and nano-vesicular delivery platform developed by Integria Care, designed to improve the absorption and stability of poorly bioavailable actives.

Source: News By Wire
https://newsbywire.com/eer-reviewed-paper-details-phytosome-quantum-nano-sphere-pqns-delivery-platform-behind-q-niflex-joint-health-nutraceutical/

The post Q-NiFlex™ and Phytosome Quantum Nano Sphere (PQNS™) Technology: A Next-Generation Multi-Target Drug Delivery Strategy for Joint Health and Osteoarthritis Management appeared first on Crassula Pharmaceuticals.

Crassula Launches Q-Niflex™ — a Joint & Cartilage-Health Dietary Supplement Powered by Integria Care’s QuanticSphere™ Delivery Platform

admin — Mon, 22 Dec 2025 02:05:27 +0000

Crassula Launches Q-Niflex — a Joint & Cartilage-Health Dietary Supplement Powered by Integria Care’s QuanticSphere Delivery Platform

Indore, India — Crassula LLC has launched Q-Niflex, a dietary supplement engineered for joint comfort, mobility, and cartilage support. Introduced at an event in Indore, Q-Niflex is the first finished consumer product to bring Integria Care’s QuanticSphere delivery platform to the Indian supplement market, pairing a Crassula-developed formulation with Integria Care’s PQNS delivery technology.

The launch reflects a two-part model behind the product. Integria Care supplies the delivery science — the QuanticSphere platform and its PQNS technology. Crassula LLC developed the finished blend and manufactures the consumer dosage form. Q-Niflex is where the two meet: an Integria Care delivery architecture inside a Crassula-formulated joint-health supplement.

The Architecture Behind Q-Niflex

QuanticSphere is Integria Care’s human-health delivery platform, and its core technology is PQNS (Phytosome Quantum Nano Sphere) — a cationic phospholipid vesicular delivery system (Patent Pending 202521095813). PQNS engineers bioactives into nano-scale phospholipid vesicles, 100–200 nm in size, designed to shield sensitive compounds from degradation in the digestive tract and support efficient transport across biological membranes.

Q-Niflex maps that delivery architecture to a specific set of biological functions: joint comfort, mobility, and cartilage support. Rather than relying on higher doses to compensate for poor absorption, the formulation is engineered to deliver its bioactives more efficiently — the QuanticSphere approach of improving uptake at the point of delivery rather than simply increasing the amount taken.

Addressing the Absorption Challenge

Many joint- and wellness-oriented bioactives are poorly absorbed in conventional form, which can require larger doses to reach meaningful levels in the body. PQNS is designed to improve ingredient transport across biological membranes, maintain stability in the gastrointestinal environment, and support sustained availability — with attention to digestive comfort and everyday tolerability that supports long-term use.

The platform’s safety architecture is built in by design: lower effective loads, sustained rather than spiking availability, no synthetic bioenhancers (no piperine), and GRAS-status phospholipid and biopolymer carriers that are fully biodegradable.

Expert Perspectives at the Launch

Scientists from Integria Care, which developed the QuanticSphere platform, spoke to the delivery science inside Q-Niflex.

Dr. Bhawana Gupta, Chief Scientific Officer, Integria Care, described the mechanism:

“PQNS is engineered to protect bioactives and improve how efficiently they are delivered. By encapsulating ingredients in nano-scale, phospholipid-based vesicles, the technology maintains stability while supporting consistent uptake — the same delivery architecture now built into Q-Niflex.”

Dr. Lavleen Gupta, Executive Director, Science & Innovation, Integria Care, addressed the broader platform:

“QuanticSphere is a modular platform, not a single-product technology. Q-Niflex is one application, focused on joint and mobility support. The same Integria technology can be deployed across many nutritional categories as we continue to expand.”

Health and nutrition professionals attending the event noted the growing interest in better-absorbed, everyday joint-support nutrition and the role that delivery technology can play in it.

A Platform for Future Products

QuanticSphere is designed as a modular, scalable platform capable of supporting a wide range of bioactives — vitamins, minerals, botanical extracts, and other nutritional compounds. Integria Care continues to develop the platform and its technology library, while Crassula LLC plans to expand its QuanticSphere-powered product line across additional wellness categories, with Q-Niflex as the first entry.

With this launch, Integria Care’s delivery science and Crassula LLC’s formulation and manufacturing come together in a finished supplement built on a simple premise: better delivery, engineered by design — engineered by science, powered by PQNS.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

About Integria Care Integria Care develops the QuanticSphere delivery platform and the PQNS technology, supplying advanced delivery science and finished B2B blends to brand owners and manufacturers. www.integriacare.com · info@integriacare.com

About Crassula LLC Crassula LLC develops and manufactures finished consumer supplement formulations, including Q-Niflex, built on Integria Care’s QuanticSphere delivery technology.

The post Crassula Launches Q-Niflex™ — a Joint & Cartilage-Health Dietary Supplement Powered by Integria Care’s QuanticSphere™ Delivery Platform appeared first on Crassula Pharmaceuticals.

Happy Diwali

admin — Tue, 21 Oct 2025 02:57:06 +0000

Happy Diwali from all of us at Crassula Pharmaceuticals.

May this Festival of Lights bring renewed energy, health, and prosperity to every home.

As we celebrate illumination in all its forms, we remain committed to advancing science and wellness—with the same spirit of clarity and purpose that Diwali inspires.

Wishing you a bright, safe, and joyous Diwali.

The post Happy Diwali appeared first on Crassula Pharmaceuticals.

Season’s Greetings from Crassula

admin — Sun, 22 Dec 2024 19:08:28 +0000

Season’s Greetings from Crassula

As we wrap up another year of delivering quality solutions and forging new horizons in the health and wellness sector, we want to express our heartfelt appreciation for our clients, partners, and community who have entrusted us with their well-being.

This holiday season, we are filled with gratitude for every milestone reached and every partnership formed. By working together, we’re forging a stronger path toward innovation and excellence—driven by our commitment to improving lives worldwide.

Thank you for being part of our journey. May your holidays be filled with peace, joy, and good health, and may the coming year bring you continued success and happiness.

Happy Holidays and a Prosperous New Year from Crassula!

The post Season’s Greetings from Crassula appeared first on Crassula Pharmaceuticals.

India Independence Day

admin — Thu, 15 Aug 2024 04:50:35 +0000

On this special day, we join in celebrating India’s 78th Independence Day, honoring the resilience, unity, and unwavering spirit of its people. As we commemorate the journey to freedom, let us continue striving for progress and prosperity. Wishing everyone a day filled with pride and reflection. Happy Independence Day!

The post India Independence Day appeared first on Crassula Pharmaceuticals.

Crassula Launches Vascutan Plus, Irbesartan/Hydrochlorothiazide, in Honduras

admin — Wed, 08 May 2024 13:58:31 +0000

Crassula Launches Vascutan Plus, Irbesartan/Hydrochlorothiazide, in Honduras

Lauren Sacks
mayo 8, 2024
1:58 pm
No Comments

Tegucigalpa, Honduras – Continuing its commitment to cardiovascular health, Crassula Pharmaceuticals is proud to announce the release of Vascutan Plus, a combination medication containing Irbesartan and Hydrochlorothiazide, in Honduras. This new addition enhances Crassula’s portfolio by offering a comprehensive treatment solution for hypertension.

Vascutan Plus combines Irbesartan, an angiotensin II receptor blocker (ARB), with Hydrochlorothiazide, a thiazide diuretic. This synergistic combination not only effectively lowers blood pressure by relaxing blood vessels but also helps eliminate excess salt and water from the body, further reducing blood pressure and the strain on the cardiovascular system.

“Crassula Pharmaceuticals remains at the forefront of innovation in healthcare with the launch of Vascutan Plus, aimed at providing a more effective hypertension management strategy,” stated Dr. Roopesh Gupta, CEO of Crassula Pharmaceuticals. “This advanced formula is designed to meet the diverse needs of patients dealing with high blood pressure, offering them a higher level of care and support.”

Vascutan Plus is now available throughout Honduras, signifying a key advancement in the management of hypertension and its associated risks. For more information on Vascutan Plus and other products from Crassula Pharmaceuticals, please visit www.crassulapharma.com or contact sales@crassulapharma.com.

About Crassula Pharmaceuticals

Specializing in high-quality healthcare products, Crassula Pharmaceuticals focuses on innovation, quality, and patient safety to enhance health and well-being both locally and globally. The company offers a wide range of therapeutic solutions designed to address the healthcare needs of the community.

The post Crassula Launches Vascutan Plus, Irbesartan/Hydrochlorothiazide, in Honduras appeared first on Crassula Pharmaceuticals.

Crassula Pharmaceuticals Launches Vascutan, Irbesartan, in Honduras

admin — Mon, 29 Apr 2024 19:55:10 +0000

Crassula Introduces Vascutan for Advanced Hypertension Control in Honduras

Lauren Sacks
abril 29, 2024
7:55 pm
No Comments

Tegucigalpa, Honduras – Crassula Pharmaceuticals, a leader in cardiovascular healthcare solutions, is thrilled to announce the market introduction of Vascutan, an Irbesartan-based medication, in Honduras. This strategic expansion of Crassula’s cardiovascular portfolio underscores the company’s commitment to combating hypertension and associated cardiac conditions.

Irbesartan, the active ingredient in Vascutan, is a potent angiotensin II receptor blocker (ARB) that effectively lowers blood pressure by relaxing blood vessels. The introduction of Vascutan aims to provide patients with a reliable and efficient option for managing hypertension, which is a major risk factor for heart disease and stroke.

“Crassula Pharmaceuticals is dedicated to enhancing patient health through innovative and effective treatments. The launch of Vascutan demonstrates our commitment to addressing the urgent needs of hypertensive patients,” said Mr. Arturo Yidi, COO of Crassula. “We believe Vascutan will play a critical role in improving the cardiovascular health of the Honduran population.”

Vascutan is now available in Honduras, providing a new tool in the fight against high blood pressure and its complications. For more information about Vascutan and other Crassula products, please visit www.crassulapharma.com or contact sales@crassulapharma.com.

About Crassula Pharmaceuticals

Crassula specializes in high-quality healthcare products that focus on innovation, quality, and patient safety. Our mission is to improve health and well-being in Honduras and beyond, with a diverse product range that addresses various therapeutic areas and healthcare needs.

Discover the Benefits of Vascutan for Hypertension Treatment

Lowered Blood Pressure

Vascutan is a Potent Angiotensin II Receptor Blocker (ARB) that Effectively Lowers Blood Pressure

Reduced Risk of Heart Disease and Stroke

Vascutan Improves Overall Cardiovascular Health

Take Control of Your Hypertension

Manage Your Serious Health Condition with Vascutan

Peace of Mind

Choose the Best Treatment for Hypertension

Vascutan is the right choice for those seeking effective treatment for high blood pressure. With Irbesartan as its key ingredient, Vascutan is a potent Angiotensin II receptor blocker (ARB) that relaxes blood vessels and effectively manages hypertension, reducing the risk of heart disease and stroke significantly. Take control of your health today and choose Vascutan. For more information, contact us at +1 954-676-7060 or email at info@crassulapharma.com.

By clicking Learn More, you’re confirming that you agree with our Terms and Conditions.

The post Crassula Pharmaceuticals Launches Vascutan, Irbesartan, in Honduras appeared first on Crassula Pharmaceuticals.

We are proud to announce a new addition to our team at CRASSULA!

admin — Tue, 16 Apr 2024 20:16:43 +0000

We are proud to announce a new addition to our team at CRASSULA!

We are thrilled to announce an exciting new addition to our team at CRASSULA!

Please join us in welcoming Daniel Suazo as the new Medical Representative Lead at #CrassulaHonduras. Daniel comes to us with an impressive background in the healthcare sector, where he has consistently demonstrated exceptional leadership and a deep commitment to improving access to quality treatments.
In his new role, Daniel will play a crucial part in advancing our initiatives to enhance the accessibility and quality of life for patients in Honduras. We are confident that his expertise and leadership will greatly contribute to our efforts in delivering innovative and effective solutions to those in need.

Welcome aboard, Daniel! We are excited to see all the great things we will accomplish together.

#Welcome #PharmaceuticalIndustry #HealthInnovation #TeamCrassula #CrassulaHonduras

The post We are proud to announce a new addition to our team at CRASSULA! appeared first on Crassula Pharmaceuticals.

Introducing Glycedil: Revolutionizing Type 2 Diabetes Management in Honduras

admin — Tue, 26 Mar 2024 20:33:37 +0000

Introducing Glycedil: Revolutionizing Type 2 Diabetes Management in Honduras

Crassula Honduras Announces the Launch of Glycedil, Sitagliptin 100mg, in Honduras

Tegucigalpa, Honduras – In a significant expansion of its diabetes care portfolio, Crassula Pharmaceuticals proudly introduces Glycedil, a Sitagliptin 100mg tablet, to the Honduran market. This strategic launch underscores Crassula’s unwavering commitment to innovating in the field of chronic disease management and improving the quality of life for individuals living with Type 2 diabetes.

Sitagliptin, the active ingredient in Glycedil, is a highly effective dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by enhancing the body’s own ability to lower blood sugar levels, especially after meals. The 100mg dosing of Glycedil is designed to optimize blood sugar control while minimizing side effects, offering a new hope for patients seeking a more balanced approach to managing their diabetes.

“Crassula Pharmaceuticals is dedicated to advancing healthcare outcomes with accessible, innovative treatments. The launch of Glycedil is a testament to our commitment to providing effective solutions for the complex challenges faced by patients with Type 2 diabetes,” said Dr. Josué Daniel Suazo, National Sales Manager at Crassula Honduras. “We are excited to offer this new therapeutic option to the people of Honduras, further enhancing our mission to make advanced care available to all.”

Glycedil is now available across Honduras, marking a pivotal step forward in the management of Type 2 diabetes. For more information on Glycedil and other Crassula products, please visit www.crassulapharma.com or contact sales@crassulapharma.com

About Crassula Honduras

Crassula Honduras is a division of Crassula LLC., a USA based company at the forefront of developing high-quality healthcare products, focusing on innovation, quality, and patient safety to improve health and well-being both in Honduras and internationally. With a diverse product range that addresses a wide spectrum of therapeutic areas, Crassula is committed to meeting the healthcare needs of communities around the globe.

The post Introducing Glycedil: Revolutionizing Type 2 Diabetes Management in Honduras appeared first on Crassula Pharmaceuticals.

Crassula Launches Relixib, Etoricoxib 120mg Coated Tablet, in Honduras

admin — Sun, 24 Mar 2024 17:25:54 +0000

Crassula Launches Relixib, Etoricoxib 120mg Coated Tablet, in Honduras

Crassula Pharmaceuticals Launches Relixib, Etoricoxib 120mg, in Honduras

Tegucigalpa, Honduras – Crassula Honduras, a leading pharmaceutical manufacturer renowned for its commitment to quality, is excited to announce the introduction of Relixib, an etoricoxib 120mg tablet, to the Honduran market. This new addition to Crassula’s portfolio reinforces the company’s dedication to providing advanced healthcare solutions and addressing the needs of patients suffering from chronic pain and inflammation.

Etoricoxib, the active ingredient in Relixib, belongs to a class of medications known as selective COX-2 inhibitors, offering targeted relief from pain and swelling associated with various arthritic conditions, including osteoarthritis, rheumatoid arthritis, and gout. The 120mg dosage has been carefully selected to optimize efficacy while minimizing potential side effects, ensuring a better quality of life for patients.

“Through the launch of Relixib, Crassula Honduras underscores its ongoing commitment to enhance healthcare outcomes with innovative and accessible treatment options. Relixib exemplifies our mission to address unmet medical needs in the management of pain and inflammation,” stated Dr. Bhawana Gupta, CTO of Crassula Pharmaceuticals. “We are proud to offer this significant advancement in pain management to the people of Honduras, furthering our goal of making superior healthcare solutions readily accessible.”

Relixib is now available in Honduras, offering a new hope for patients seeking effective management of chronic pain and inflammatory conditions. For more information about Relixib and other Crassula Pharmaceuticals products, please visit www.crassulapharma.com or contact sales@crassulapharma.com.

About Crassula Honduras

Crassula Honduras is a division of Crassula Pharmaceuticals, a company synonymous with high-quality healthcare products. With a focus on innovation, quality, and patient safety, Crassula strives to improve health and well-being in Honduras and beyond. The company’s diverse product portfolio meets a wide range of healthcare needs, ensuring that patients have access to the latest advancements in medical treatment.

The post Crassula Launches Relixib, Etoricoxib 120mg Coated Tablet, in Honduras appeared first on Crassula Pharmaceuticals.